Melanotan II Complete Guide: Dosage, Tanning Results & Safety

What Is Melanotan II?

Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) originally developed at the University of Arizona in the 1990s. The peptide was designed to stimulate melanogenesis — the body's natural process of producing melanin pigment — as a potential strategy to reduce skin cancer risk by providing a protective tan without extensive UV exposure.

MT-II is a cyclic heptapeptide with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. It acts as a non-selective agonist at melanocortin receptors, particularly MC1R (melanogenesis), MC3R (energy homeostasis), MC4R (sexual function and appetite), and MC5R (exocrine gland function). This broad receptor activity explains why MT-II produces effects beyond just tanning — most notably its well-documented effect on sexual arousal and erectile function. For context on how peptides work generally, see our What Are Peptides? overview.

It is important to note upfront that Melanotan II is not approved by the FDA or any major regulatory agency for human use. It is classified as a research peptide. Several regulatory agencies, including the FDA, TGA (Australia), and MHRA (UK), have issued warnings about its use. This article reviews the research objectively but does not constitute an endorsement of use.

How MT-II Stimulates Melanogenesis

Understanding how MT-II produces a tan requires understanding the normal melanogenesis pathway:

Normal Tanning. When UV radiation hits the skin, keratinocytes release alpha-MSH, which binds to MC1R receptors on melanocytes. This activates a signaling cascade (cAMP/PKA/MITF) that upregulates tyrosinase, the rate-limiting enzyme in melanin production. Melanin is then packaged into melanosomes and transferred to surrounding keratinocytes, producing visible pigmentation.

MT-II Mechanism. Melanotan II bypasses the UV trigger by directly activating MC1R. It binds with higher affinity than natural alpha-MSH and has a longer half-life, producing sustained melanocortin signaling. The result is melanin production even without UV exposure, though most protocols include some minimal UV exposure to distribute melanin evenly and activate the full melanogenesis cascade.

Eumelanin vs Pheomelanin. MT-II preferentially stimulates eumelanin production (the brown-black protective pigment) over pheomelanin (the red-yellow pigment associated with fair skin and increased skin cancer risk). This shift in melanin composition is part of the original photoprotective rationale for the peptide's development.

Tanning Effects and What to Expect

The tanning effects of MT-II follow a predictable pattern based on dosing phase:

Loading Phase (Weeks 1-3). During the initial loading phase, users typically notice skin darkening beginning around days 5-10. The face, arms, and other areas with higher melanocyte density darken first. Existing moles and freckles will darken disproportionately — this is normal and expected, as these areas have concentrated melanocytes.

Maintenance Phase. Once the desired level of pigmentation is achieved, the dose is reduced to maintain the tan. The maintenance dose is typically lower and less frequent than the loading dose. Some users can maintain pigmentation with only 1-2 doses per week.

Individual Variation. Response to MT-II varies significantly based on baseline skin type. Individuals with Fitzpatrick skin types I-II (very fair, burns easily) will see the most dramatic change but may take longer to achieve it. Skin types III-IV typically respond faster and more evenly. Skin types V-VI generally do not need melanogenic peptides.

UV Exposure. While MT-II can produce pigmentation without UV, most protocols recommend brief, controlled sun exposure or low-duration tanning bed sessions during the loading phase. This serves to activate the full melanogenesis cascade and distribute melanin more evenly. Importantly, the UV exposure needed is substantially less than would be required for natural tanning — typically 10-15 minutes of moderate sun rather than extended sessions.

Sexual Function Effects

MT-II's activity at MC4R produces notable effects on sexual function, which led to the development of the related peptide PT-141 (Bremelanotide) — an FDA-approved medication for hypoactive sexual desire disorder in women.

Erectile Function. In early clinical trials at the University of Arizona, MT-II produced spontaneous erections in male subjects, even without visual or physical sexual stimulation. This effect is mediated by MC4R signaling in the central nervous system, not by peripheral vascular mechanisms like PDE5 inhibitors (Viagra, Cialis). The erections are centrally mediated — they originate from brain signaling rather than direct vascular smooth muscle relaxation.

Libido Enhancement. Both male and female subjects in clinical studies reported increased sexual desire and arousal. This is a centrally mediated effect distinct from the erectile mechanism and is the basis for PT-141's FDA approval for female hypoactive sexual desire disorder.

PT-141 Connection. PT-141 was derived from MT-II specifically to isolate the sexual function effects while minimizing the melanogenic and other off-target effects. PT-141 is a truncated, linear fragment of MT-II with more selective MC4R activity. Visit our PT-141 compound page for the full breakdown of this FDA-approved derivative.

Dosage Protocols

MT-II is administered via subcutaneous injection. For injection technique, see our How to Inject Peptides guide. For reconstitution instructions, see How to Reconstitute Peptides.

Starting Low. Beginning with a low test dose (100-250 mcg) is strongly recommended. Nausea is the most common side effect and is dose-dependent. Many users find that 250 mcg produces adequate tanning effects with manageable side effects, while doses above 500 mcg increase side effects without proportional tanning benefit.

Timing. Many users administer MT-II before bed to sleep through the nausea that can occur in the first 1-2 hours after injection. Evening dosing also avoids the facial flushing that some users experience. For accurate dose calculation, use our Peptide Calculator.

Side Effects and Safety Concerns

MT-II has a more significant side effect profile than many peptides, reflecting its non-selective melanocortin receptor activity:

Common Side Effects (occur in most users):

• Nausea — the most frequently reported side effect, occurring in 50-80% of users at standard doses. Usually worst during the first few doses and diminishes with continued use. Dose-dependent.
• Facial flushing — warmth and redness of the face lasting 30-60 minutes after injection
• Appetite suppression — mediated by MC4R; can be pronounced in some individuals
• Spontaneous erections (males) — can be inconvenient and is a hallmark MC4R effect
• Darkening of existing moles and nevi — expected with increased melanogenesis

Uncommon but Important Side Effects:

• New mole development — reports of new nevi appearing during MT-II use raise concerns about melanocyte proliferation
• Changes in existing moles — any asymmetry, border irregularity, or rapid growth in existing moles should prompt immediate dermatological evaluation
• Hyperpigmentation — uneven darkening, particularly in skin folds, genital area, and around the lips
• Fatigue and lethargy — reported by some users, particularly at higher doses

Serious Safety Concerns:

• Melanoma risk — this is the most debated safety concern. While MT-II was originally designed to reduce skin cancer risk by promoting photoprotective eumelanin, concerns exist that stimulating melanocyte proliferation could promote melanoma in individuals with pre-existing atypical nevi or melanoma risk factors. Case reports of melanoma in MT-II users exist, though causation versus correlation has not been established.
• Lack of long-term safety data — there are no long-term controlled safety studies of MT-II in humans. The peptide was not advanced through full clinical development for melanogenic use.

For general peptide safety principles, visit our Are Peptides Safe? page and Peptide Side Effects overview.

Melanotan II vs Melanotan I

Melanotan I (afamelanotide) is a linear alpha-MSH analog with more selective MC1R activity compared to MT-II's broad melanocortin receptor profile:

Melanotan I (marketed as Scenesse) is FDA-approved for erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme sun sensitivity. Its more selective receptor profile makes it a safer option for melanogenesis but it is only available by prescription for EPP patients.

Legal Status

MT-II is not approved for human use by any major regulatory agency. It is available as a research chemical, but multiple agencies have taken enforcement actions against companies marketing it for human use. Australia's TGA and the UK's MHRA have been particularly active in warning consumers about unlicensed MT-II products. For the broader legal landscape, see Are Peptides Legal? and our FDA Peptide Regulations 2026 overview.

The Bottom Line on Melanotan II

Melanotan II is one of the most effective melanogenic compounds ever studied, capable of producing significant skin pigmentation with minimal UV exposure. Its dual tanning and sexual function effects — both well-documented in clinical studies — make it unique among peptides. However, its non-selective melanocortin receptor activity produces significant side effects including nausea, appetite changes, and spontaneous sexual arousal. The most serious concern is the theoretical risk of promoting melanocyte proliferation in individuals with melanoma risk factors.

Anyone considering MT-II should have a thorough dermatological evaluation before use, monitor all moles and nevi closely during use, and understand that no long-term controlled safety data exists. The development of MT-I (afamelanotide/Scenesse) for clinical use and PT-141 (bremelanotide) for sexual function represents the pharmaceutical industry's effort to isolate the beneficial effects of melanocortin signaling while improving selectivity and safety.